Agonists of the Chemokine Receptor Cxcr3

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to a new class of small molecules that act as agonists (activators) of the chemokine receptor CXCR3, a protein involved in immune cell signaling and inflammation. The patent discloses the chemical structure of these agonists, methods for their synthesis, and their selective activity in activating specific signaling pathways (biased agonism), either favoring β-arrestin recruitment/internalization or G-protein signaling. The compounds can be used as pharmaceuticals for treating a wide range of inflammatory diseases, cancer, diabetes, transplant rejection, Alzheimer's disease, ischemia, and improving wound healing. They can also serve as research probes for understanding CXCR3 receptor biology.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of auto-immune and inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.
• Cancer therapeutics—prevention of tumor growth and metastasis by modulating immune responses.
• Therapeutic intervention in metabolic disorders like type 1 diabetes mellitus.
• Prevention of transplant rejection by immune modulation.
• Treatment of neurodegenerative diseases such as Alzheimer's disease and HIV-induced dementia.
• Cardiovascular and ischemic event management, including stroke and myocardial infarction.
• Support for wound healing and tissue repair.
• Investigation of CXCR3 signaling pathways as research tools in drug discovery and immunology.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new class of selective (biased) CXCR3 agonists that can target specific cell signaling pathways, minimizing side effects seen with non-specific activation.
• Addresses the unmet medical need for safer, more targeted therapies for inflammatory, autoimmune, and cancer diseases by fine-tuning immune responses.
• Potential for improved safety profile compared to corticosteroids and other non-specific anti-inflammatory drugs, reducing unwanted side effects.
• Versatile applicability across a broad spectrum of diseases that involve inflammation and immune cell migration.
• Enables research into the molecular mechanisms of biased signaling at GPCRs, fostering the development of next-generation therapeutics.
• Pharmaceutical compositions can be tailored to exert either β-arrestin or G-protein pathway selectivity, offering precision medicine strategies.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to agonists of the chemokine receptor CXCR3, methods of their synthesis and uses thereof.